Atopic Dermatitis

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 384(12), P. 1136 - 1143

Published: March 24, 2021

Atopic dermatitis is a chronic disorder that usually starts in childhood but often persists adulthood. The appearance and extent of lesions vary with age race or ethnic group. Topical systemic treatments targeting the underlying immune condition have been introduced.

Language: Английский

---

Atopic dermatitis in the pediatric population

Annals of Allergy Asthma & Immunology, Journal Year: 2021, Volume and Issue: 126(4), P. 417 - 428.e2

Published: Jan. 9, 2021

Little is known on the current global prevalence of atopic dermatitis (AD) in pediatric population.To estimate real-world AD population and by disease severity.This international, cross-sectional, web-based survey children adolescents (6 months to <18 years old) was conducted following 18 countries: North America (Canada, United States), Latin (Argentina, Brazil, Columbia, Mexico), Europe (France, Germany, Italy, Spain, Kingdom), Middle East Eurasia (Israel, Saudi Arabia, Turkey, Arab Emirates, Russia), Asia (Japan, Taiwan). Prevalence determined using 2 definitions: (1) diagnosed as having according International Study Asthma Allergies Childhood (ISAAC) criteria self- or parent-report ever being told a physician that they their child had (eczema); (2) reported based ISAAC only. Severity assessed Patient Global Assessment (PtGA) Patient-Oriented Eczema Measure (POEM).Among 65,661 responders, 12-month (ISAAC plus self-reported diagnosis) ranged from 2.7% 20.1% across countries; only) 13.5% 41.9%. Severe evaluated with both PtGA POEM generally less than 15%; more subjects rated mild suggested POEM. No trends were observed age sex; lower rural residential settings urban suburban.This countries revealed affects substantial proportion population. Although severity varied groups countries, 15% severe AD.

Language: Английский

---

Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases

Journal of Clinical Investigation, Journal Year: 2019, Volume and Issue: 129(4), P. 1493 - 1503

Published: March 10, 2019

A rapidly developing paradigm for modern health care is a proactive and individualized response to patients’ symptoms, combining precision diagnosis personalized treatment. Precision medicine becoming an overarching medical discipline that will require better understanding of biomarkers, phenotypes, endotypes, genotypes, regiotypes, theratypes diseases. The 100-year-old allergen-specific management allergic diseases has particularly contributed early awareness in medicine. Polyomics, big data, systems biology have demonstrated profound complexity dynamic variability disease between individuals, as well regions. Escalating costs together with questionable efficacy the current facilitated emergence endotype-driven approach. We describe here approach stratifies patients based on mechanisms optimize

Language: Английский

---

Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis

JAMA Dermatology, Journal Year: 2019, Volume and Issue: 155(12), P. 1358 - 1358

Published: Oct. 9, 2019

Molecular profiling of skin biopsies is the criterion standard for evaluating cutaneous atopic dermatitis (AD) phenotype. However, are not always feasible in children. A reproducible minimally invasive approach that can track disease pediatric longitudinal studies or clinical trials lacking.To assess a using tape strips to identify biomarkers may serve as surrogate identified whole-tissue biopsies.This cross-sectional study 51 children younger than 5 years recruited with moderate severe AD and without from dermatology outpatient clinics at children's hospital. Sixteen were serially collected nonlesional lesional 21 who had less 6 months initiation normal 30 did have between January 22, 2016, April 20, 2018.Gene protein expression evaluated quantitative real-time polymerase chain reaction immunohistochemistry.A total included study; duration, AD. Of AD, mean (SD) age was 1.7 (1.7) years, most male (15 [71.4%] white [71.4%]). 1.8 (2.0) female (20 [66.7%]) (22 [73.3%]). Seventy-seven 79 immune barrier gene products detected (gene detection rate, 97%) 70 71 (sample 99%), 53 markers differentiating and/or Many cellular T cells (CD3), AD-related dendritic (Fc ε RI OX40 ligand receptors), key inflammatory (matrix metallopeptidase 12), innate (interleukin 8 [IL-8] IL-6), helper cell 2 (TH2; IL-4, IL-13, chemokines CCL17 CCL26), TH17/TH22 (IL-19, IL-36G, S100A proteins) genes significantly increased compared skin. For example, IL-4 (SE) -15.2 (0.91) -19.5 (0.48); P < .001. Parallel decreases occurred epidermal (FLG, CLDN23, FA2H) negative regulators (IL-34 IL-37). decrease FLG -2.9 (0.42) 2.2 (0.45); Associations found severity transepidermal water loss TH2 (IL-33 IL-4R) (IL-36G S100As) (evaluated SCORing Atopic Dermatitis, Eczema Area Severity Index, Pruritus Dermatitis Quickscore tools).In this study, provide alternative AD-associated prove useful tracking therapeutic response predicting future course comorbidities.

Language: Английский

---

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

Journal of the American Academy of Dermatology, Journal Year: 2021, Volume and Issue: 85(1), P. 62 - 70

Published: Feb. 17, 2021

Language: Английский

---

The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment

Cellular and Molecular Immunology, Journal Year: 2023, Volume and Issue: 20(5), P. 448 - 474

Published: March 16, 2023

Atopic dermatitis (AD) is the most common inflammatory skin disease, and it considered a complex heterogeneous condition. Different phenotypes of AD, defined according to patient age at onset, race, ethnic background; disease duration; other characteristics, have been recently described, underlying need for personalized treatment approach. Recent advancements in understanding AD pathogenesis resulted real translational revolution led exponential expansion therapeutic pipeline. The study biomarkers clinical studies emerging treatments helping clarify role each cytokine immune pathway will allow addressing unique fingerprints subset. Personalized medicine be ultimate goal this targeted research. In review, we discuss changes concepts both approach highlight scientific rationale behind report recent efficacy data.

Language: Английский

---

Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

British Journal of Dermatology, Journal Year: 2023, Volume and Issue: 189(5), P. 531 - 539

Published: July 18, 2023

Abstract Background Atopic dermatitis (AD) is an inflammatory skin disease with significant unmet need. Blockade of the OX40–OX40 ligand (OX40L) costimulation pathway by targeting OX40L on antigen-presenting cells (APCs) a fully human noncytotoxic, nondepleting anti-OX40L monoclonal antibody (amlitelimab; SAR445229; KY1005) novel way to modulate persistent inflammation. Objectives To assess safety and efficacy amlitelimab over 16 weeks in adults AD phase IIa double-blind placebo-controlled study. Methods The study was conducted at 19 hospitals Germany, Poland, Spain UK. Eligible patients moderate-to-severe were randomized (1 : 1 1) low-dose intravenous (IV) (200 mg), high-dose IV (500 mg) or placebo, followed three maintenance doses (50% loading dose) 4, 8 12 weeks, follow-up week 36. co-primary endpoints incidence treatment-emergent adverse events (all who received ≥ dose drug) mean percentage change Eczema Area Severity Index (EASI) (full analysis set). Results Between 13 December 2018 May 2020, 89 randomly assigned low- (n = 29) 30) placebo 29), whom 88 proceeded treatment [37 women (42%), 51 (58%) men; (SD) age 33.6 (11.9) years]. Amlitelimab generally well tolerated unremarkable profile; no hypersensitivity reported. For primary endpoint, least square EASI from baseline –80.12% [95% confidence interval (CI) –95.55 –64.68; P 0.009 vs. placebo] –69.97% (95% CI –85.04 –54.60; 0.07 placebo) for 27) groups, respectively, –49.37% –66.02 –32.72) 24). Numerically greater reductions observed 2 16. Conclusions Novel OX40L-expressing APCs resulted clinically meaningful improvements AD.

Language: Английский

---

Disease modification in inflammatory skin disorders: opportunities and challenges

Nature Reviews Drug Discovery, Journal Year: 2023, Volume and Issue: 22(8), P. 662 - 680

Published: July 13, 2023

Language: Английский

---

New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines

Annals of Allergy Asthma & Immunology, Journal Year: 2019, Volume and Issue: 124(1), P. 28 - 35

Published: Oct. 14, 2019

Language: Английский

---

Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis

Journal of Allergy and Clinical Immunology, Journal Year: 2019, Volume and Issue: 144(4), P. 1011 - 1024

Published: July 26, 2019

Language: Английский

---